3 recruiting, 1 completed, 1 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 3, Completed 1, Terminated 1 |
Follow Advanced Breast Carcinoma: new trials by email Literature Review of Advanced Breast Carcinoma trials Research Report on Advanced Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype Trastuzumab deruxtecan (T-DXd, DS-8201a), CDK4/6i plus ET - Advanced Breast Cancer, Advanced Breast Carcinoma | Phase 2 | Recruiting | MedSIR | 200 | 2025-06-30 | 2026-07-30 |
| A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Abemaciclib, Biopsy, Bone Scan - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 6 | 2025-06-24 | 2026-04-28 |
| At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment - Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 220 | 2023-08-23 | 2026-04-20 |
| Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer Cediranib, Ceralasertib, Olaparib - Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 60 | 2020-07-28 | 2026-09-14 |
| TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer Anastrozole, Denifanstat, Exemestane - Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma | Phase 2 | Completed | Mayo Clinic | 17 | 2017-08-03 | 2026-10-09 |
Breast Neoplasms (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1)
Neoplasms (3) · Neoplasms by Site (2) · Adnexal Diseases (1) · Blood Protein Disorders (1) · Bone Marrow Diseases (1) · Breast Diseases (1) · Cardiovascular Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1)
Biopsy (2) · Letrozole (2) · exemestane (2) · Anastrozole (1) · CT-P6 (1) · Disulfides (1) · Fulvestrant (1) · Gemcitabine (1) · Home Care Services (1) · House Calls (1) · Magnetic Resonance Spectroscopy (1) · Ogivri (1) · Ontruzant (1) · PF-05280014 (1) · Paclitaxel (1)
Mayo Clinic (2) · M.D. Anderson Cancer Center (1) · MedSIR (1) · OHSU Knight Cancer Institute (1)
United States (4) · Austria (1) · Belgium (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Portugal (1) · Spain (1) · United Kingdom (1)
Banu Arun (1) · Charles D Lopez, MD, PhD (1) · Roxana S. Dronca, MD (1) · Tufia C. Haddad, M.D. (1)